Evidence map›Paper›PMID 40724574›Full record

ArticleLife (Basel, Switzerland)2025

Gastrointestinal Cancers with Consideration of DPD and UGT1A1 Plasma Levels: Chemotherapy-Related Toxicity.

Velko Minchev, Hristo Tsankov, Bozil Robev, Martin Takov, Stefan Federchev, Kalina Kamenova, Lozan Todorov, Liliya Atanasova, Nadya Hristova-Avakumova, Rumen Nikolov and 2 more

Abstract read
In one paragraph

Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Velko MinchevDepartment of Medical Oncology, SofiaMed University Hospital, 1113 Sofia, Bulgaria.
Hristo TsankovDepartment of Medical Oncology, SofiaMed University Hospital, 1113 Sofia, Bulgaria.
Bozil RobevHematology Clinic, Department of Medical Oncology, UMHAT "St. Ivan Rilski", 9002 Sofia, Bulgaria.
Martin TakovFaculty of Pharmacy, Medical University-Sofia, 1431 Sofia, Bulgaria.
Stefan FederchevMedical Faculty, Medical University-Sofia, 1431 Sofia, Bulgaria.
Kalina KamenovaDepartment of Medical Chemistry and Biochemistry, Medical Faculty, Medical University-Sofia, 1431 Sofia, Bulgaria.ORCID 0000-0001-6165-0443
Lozan TodorovDepartment of Chemistry, Faculty of Pharmacy, Medical University-Sofia, 1431 Sofia, Bulgaria.ORCID 0000-0002-7230-8368
Liliya AtanasovaDepartment of Medical Physics and Biophysics, Medical Faculty, Medical University-Sofia, 1431 Sofia, Bulgaria.
Nadya Hristova-AvakumovaDepartment of Medical Physics and Biophysics, Medical Faculty, Medical University-Sofia, 1431 Sofia, Bulgaria.
Rumen NikolovDepartment of Pharmacology and Toxicology, Medical Faculty, Medical University-Sofia, 1431 Sofia, Bulgaria.
Pavlina GatevaDepartment of Pharmacology and Toxicology, Medical Faculty, Medical University-Sofia, 1431 Sofia, Bulgaria.ORCID 0000-0002-3791-8654
Vanyo MitevDepartment of Medical Chemistry and Biochemistry, Medical Faculty, Medical University-Sofia, 1431 Sofia, Bulgaria.ORCID 0000-0001-7528-590X

Funding

Bulgarian National Science Fund KP06-M63/5
6 · The paper itself

Abstract

Unpredictable, dose-limiting toxicity remains a challenge in cancer treatment. We evaluated dihydropyrimidine dehydrogenase (DPD) and UDP-glucuronosyltransferase 1A1 (UGT1A1) plasma levels in the context of chemotherapy-induced toxicity and disease progression. Seventy gastrointestinal cancer patients (30 FOLFOX; 40 FOLFIRI) were enrolled. DPD and UGT1A1 plasma levels were determined using ELISA. Univariable and bivariable analyses and a general linear model (GLM) framework were used. Post-infusional reductions in white blood cell and granulocyte counts were observed. For FOLFOX, the granulocyte counts decreased by 17% (r = 0.54;

Indexed as

dihydropyrimidine dehydrogenaseFOLFIRIFOLFOXgastrointestinal malignanciesmyelotoxicityUDP-glucuronosyltransferase

Identifiers

PMID40724574
PMCPMC12300698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.